KRAS and colorectal cancer: As the finding indicated that the efficacy of “cetuximab after oxaliplatin” was not restricted to the KRAS/BRAF wild-type background, the experiment was repeated using a panel of seven other colorectal cancer cell lines, representing variable KRAS/BRAF genotypes (Table 1).